Interim Report 2026
Filed with HKEX · Stock code 8158 · · 42 pages · English and Chinese
CHARACTERISTICS OF GEM (“GEM”) OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”) 香港聯合交易所有限公司（「聯交 所 」）GEM（「 GEM 」）之特點 GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in
China Regenerative Medicine International Limited on 6ix
Earlier from China Regenerative Medicine International
- CEO Mr. Chen Chunguo Holds a Meeting with Government Official of Shaanxi Xixian New Area - Discuss the Strategic Deployment of Regenerative Medicine Industry Develop Hi-tech Cosmeceuticals Industrial Park
- R&D Team of “Acornea” Invited to Share the R&D and Application Experience of the First Chinese Bio- engineered Cornea at Oxford
- China Regenerative Medicine International: “Acornea” expands clinical applications Completed FDA registration
- Financial Secretary of HK SAR Paul Chan Mo-po Leads Delegation on Visit to the Group Encourages to Promote the Innovative Technology Development of Regenerative Medicine
- Fund Invested to Acquire U.S Cosmeceuticals Brand-Obagi
Later from China Regenerative Medicine International
- Letter to Registered Shareholder - New Arrangements on Dissemination of Corporate Communications and Reply Form
- Letter to Non-registered Shareholder - New Arrangements on Dissemination of Corporate Communications
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
Follow China Regenerative Medicine International into a list and get an email when it puts out news.
Follow China Regenerative Medicine International